Alumis Inc. Common Stock (ALMS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in South San Francisco, CA, United States. The current CEO is Martin Babler.
ALMS has IPO date of 2021-02-22, 168 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $2.82B.
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for autoimmune and neuroinflammatory disorders. The company's lead candidate, ESK-001, is an allosteric tyrosine kinase 2 (TYK2) inhibitor in development for plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Additionally, Alumis is advancing A-005, a brain-penetrant TYK2 inhibitor designed to treat neuroinflammatory and neurodegenerative diseases. Founded in 2021 and formerly known as Esker Therapeutics, the company rebranded to Alumis Inc. in January 2022 and is headquartered in South San Francisco, California.
